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Neil H. Shear1,2,5,9,10 and Colin R. Dormuth8 for the Canadian Drug Safety and Effectiveness Research
Network
Limited evidence suggests that isotretinoin may be associated with inflammatory bowel disease (IBD). To explore
this association, we conducted a retrospective population-based cohort study in British Columbia, Canada,
among participants who were newly treated with isotretinoin or topical acne medications. The entire population
of untreated provincial residents aged 12–29 years served as the reference group. During the 12-year study
period, we identified 46,922 participants treated with isotretinoin, 184,824 treated with a topical acne medication,
and 1,526,946 untreated individuals. Compared with untreated individuals, we observed no significant association
between isotretinoin use and IBD (rate ratio (RR) 1.14; 95% confidence interval (CI) 0.92–1.41). As expected, we
found no association with topical acne medications (RR 1.11; 95% CI 0.99–1.24). In prespecified secondary
analyses, isotretinoin was associated with IBD among individuals aged 12–19 years (RR 1.39; 95% CI 1.03–1.87) and
topical acne medications were associated with ulcerative colitis (RR 1.19; 95% CI 1.00–1.42). Our primary analyses
found no association between isotretinoin and IBD. In prespecified secondary analyses, some evidence was
found of associations with isotretinoin as well as topical acne medications, suggesting a possible association
between IBD and acne itself. Additional research is needed to explore this possibility.
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INTRODUCTION
Isotretinoin is a synthetic retinoid widely used for the treatment
of severe nodulocystic acne. It is considerably more effective
than other therapies and can produce long-term remission (Chen
et al., 2002). However, isotretinoin therapy is associated with
significant adverse effects including hypertriglyceridemia,
xerostomia, intracranial hypertension, and severe teratogenicity
(Brelsford and Beute, 2008). The association with depression
and suicidal ideation remains controversial, with a recent study
suggesting that the association could be with acne rather than
isotretinoin (Hull and D’Arcy, 2003; Sundstrom et al., 2010).
More recently, some reports linked isotretinoin to inflammatory
bowel disease (IBD) (Reniers and Howard, 2001).
IBD is a debilitating disease affecting young adults world-
wide (Hanauer, 2006). A suspected association between
isotretinoin and IBD has prompted numerous lawsuits, some
of them culminating in substantial awards (Voreacos and
Martin, 2010). A review of 85 cases reported to the US
Food and Drug Administration determined, using the Naranjo
probability scale, that in 73% of instances, the association
between isotretinoin use and IBD was either probable or
highly probable (Naranjo et al., 1981; Reddy et al., 2006).
However, uncertainty remains about the association between
isotretinoin and IBD. Two observational studies have offered
conflicting conclusions, with one showing no association and
the other showing a strong association with ulcerative colitis
(UC) but not Crohn’s disease (Bernstein et al., 2009; Crockett
et al., 2010). These studies had a small number of events and
failed to adjust for the use of other medications.
Several mechanisms may underlie an association between
isotretinoin and IBD (Shale et al., 2009). Retinoids inhibit
neutrophil chemotaxis, and impaired neutrophil activity has
been implicated in the pathogenesis of Crohn’s disease (Norris
et al., 1987; Marks et al., 2006). Furthermore, isotretinoin
increases the expression of gut homing markers, which may
promote T-cell-mediated intestinal inflammation (Kang et al.,
2007).
It remains unclear whether isotretinoin therapy is associated
with IBD. Because case reports are rarely definitive proof of
causation, and because a randomized controlled trial exploring
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drug-related harm is unlikely, observational studies are the best
means of exploring the potential association between isotreti-
noin therapy and IBD. We used the comprehensive population-
based health care records of approximately 4.5 million
residents of British Columbia, Canada to examine the associa-
tion between isotretinoin use and the risk of developing IBD.
RESULTS
During the 12-year study period, we identified 46,922 patients
treated with isotretinoin, 184,824 patients treated with a
topical acne medication, and 1,526,946 untreated individuals.
Because the study design allowed individuals in any group to
reenter the analysis, the untreated group contributed a total of
more than 9 million observations. The baseline characteristics
for all groups are shown in Table 1. Compared with untreated
patients, those treated with isotretinoin were less likely to have
a low-income status and, as expected, were more likely to
have been previously exposed to tetracyclines and erythro-
mycin. They were also more likely to be male compared with
those who received topical acne medication (54% vs. 38%,
respectively), an expected finding in light of the drug’s
teratogenicity.
Acne therapy and incident IBD
Among patients with no history of IBD in the 5 years
before index date, we identified 11,408 first medical encoun-
ters for IBD during follow-up, including 87 patients in the
isotretinoin-treated cohort, 316 in the topical acne medication
cohort, and 11,005 in the reference group (Tables 2 and 3).
In the primary adjusted analysis, compared with untreated
participants, we found no association between IBD and the
use of isotretinoin (rate ratio 1.14; 95% confidence interval
(CI) 0.92–1.41) or topical acne medications (rate ratio 1.11;
95% CI 0.99–1.24).
We tested the robustness of our findings in prespecified
analyses according to age and disease type. Among patients
aged 12–19 years, isotretinoin use was associated with a
significant risk of IBD compared with no treatment (rate ratio
1.39; 95% CI 1.03–1.87), but no such association was evident
in patients aged 20–29 years (rate ratio 0.93; 95% CI 0.67–
1.29). A similar but nonsignificant trend was evident among
young patients using topical acne medications (rate ratio 1.15;
95% CI 0.98–1.36) but not older patients (rate ratio 1.07; 95%
CI 0.91–1.25). In an analysis of IBD subtype, we found no
significant association between isotretinoin therapy and IBD
among patients with UC (rate ratio 1.31; 95% CI 0.96–1.80) or
Crohn’s disease (rate ratio 1.17; 95% CI 0.90–1.52). We did find
a modest but statistically significant association between topical
acne medications and UC (rate ratio 1.19; 95% CI 1.00–1.42)
but not Crohn’s disease (rate ratio 1.07; 95% CI 0.93–1.23).
When we used a stricter definition of IBD requiring two
clinical encounters or one encounter with the subsequent
prescription of medications used to treat IBD, we again found
no significant association between isotretinoin and IBD (rate
ratio 1.14; 95% CI 0.92–1.41). However, the previously
observed association between isotretinoin and IBD in younger
patients was again documented in this analysis (rate ratio 1.39;
95% CI 1.03–1.87).
Hospitalization for exacerbations of IBD
Patients with a history of IBD may be particularly prone
to disease exacerbations following exposure to potential
triggers. Among patients with IBD, we found that those
treated with isotretinoin were not at an increased risk of
Table 1. Patient characteristics
Isotretinoin
Topical acne
medications
Unexposed
group
Patients with no history of IBD
Number of patients1 46,922 184,824 1,526,946
Number of
observations
54,614 239,144 9,533,230
Age, mean (SD) 19 (4) 18 (5) 20 (5)
Female, % 46 62 48
Low-income
status, %
23 25 31
Medication use, %
Contraceptives2 23 20 24
Tetracyclines 48 13 2
Erythromycin 11 6 3
NSAIDs 8 8 7
Previous GI
visits, %3
3 4 1
Previous non-GI
visits, %3
98 94 25
Patients with history of IBD
Number of
patients1
326 1,518 18,088
Number of
observations
349 1,791 60,454
Age, mean (SD) 21 (4) 21 (5) 23 (5)
Female, % 51 64 54
Low-income
status, %
30 33 38
Medication use, %
Contraceptives2 33 35 35
Tetracyclines 47 12 4
Erythromycin 10 6 5
NSAIDs 14 14 12
Previous GI
visits, %3
46 49 44
Previous non-GI
visits, %3
99 98 92
IBD
hospitalization, %3
11 16 11
Abbreviations: GI, gastrointestinal; IBD, inflammatory bowel disease;
NSAIDs, nonsteroidal antiinflammatory drugs.
1The design allowed patients to enter different cohorts at different times
after lapses of at least 365 days with no relevant medications, allowing
some patients to represent multiple observations. Patient characteristics in
the table reflect average characteristics across all observations, including
multiple observations for some patients.
2Among females.
3In 365 days before index date.
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subsequent hospital admission for IBD (rate ratio 0.75; 95%
CI 0.44–1.27) relative to untreated patients, whereas treatment
with topical acne medications was associated with a signifi-
cantly higher risk (rate ratio 1.38; 95% CI 1.16–1.63; Table 4).
DISCUSSION
In this population-based cohort study of nearly 50,000
isotretinoin-treated patients, we found that the isotretinoin
therapy was not associated with physician visits or hospital
admissions for IBD, although a weak but significant associa-
tion was apparent in a prespecified analysis among subjects
aged 12–19 years. However, we also found an association
between topical acne medications and UC, suggesting that IBD
may be associated with acne itself, rather than its treatment.
Previous research on the potential association between
isotretinoin and IBD has yielded conflicting results. One
negative study was limited by relatively few events, whereas
a positive study did not account for medications and condi-
tions that might be associated with IBD (Bernstein et al., 2009;
Crockett et al., 2010). Importantly, our analysis adjusted for
previous use of oral tetracyclines, which have been linked to
increased risk of IBD (Margolis et al., 2010). No previous
study has examined the association between topical acne
medications and IBD. We planned this analysis to
contextualize any observed association between isotretinoin
and IBD. We found that the risk of IBD during isotretinoin
therapy was very similar to that seen with topical acne
medications. Overall, our findings offer reassurance that
isotretinoin does not confer a major increase in the risk of IBD.
We speculate that a previously unrecognized association
exists between IBD and acne itself, rather than its treatment.
In this context, acne could be viewed as a systemic inflam-
matory condition rather than an exclusively cutaneous dis-
ease. This is not an entirely novel concept—systemic
Table 2. Association between isotretinoin and IBD
Events among
isotretinoin group
(n¼54,614)1
Events among
unexposed group
(n¼9,533,230)1
Unadjusted rate
ratio (95%
confidence interval)
Adjusted rate ratio
(95% confidence
interval)2
Primary outcome
IBD 87 11,005 1.34 (1.09–1.66) 1.14 (0.92–1.41)
Subgroup analyses
12–19 Years 50 3,318 1.80 (1.36–2.39) 1.39 (1.03–1.87)
20–29 Years 37 7,687 1.24 (0.90–1.72) 0.93 (0.67–1.29)
UC 41 4,612 1.51 (1.11–2.05) 1.31 (0.96–1.80)
Crohn’s disease 60 7,263 1.40 (1.09–1.81) 1.17 (0.90–1.52)
Abbreviations: IBD, inflammatory bowel disease; UC, ulcerative colitis.
1The number of observations (n) in each group includes multiple observations for some patients, because patients were allowed to enter different cohorts at
different times, or reenter the same cohort, following a period of no prescription of relevant medications forX365 days. There were 46,922 unique patients in
the isotretinoin group and 1,526,946 in the unexposed group.
2Poisson regression model estimates adjusted for age; sex; socioeconomic status; receipt in the year preceding cohort entry of tetracyclines, erythromycin, oral con-
traceptives, or nonsteroidal antiinflammatory drugs; any physician visit or hospital admission; and any gastrointestinal diagnosis in the year preceding cohort entry.
Table 3. Association between topical acne medications and IBD
Events among
topical acne group
(n¼239,144)1
Events among
unexposed group
(n¼9,533,230)1
Unadjusted rate
ratio (95%
confidence interval)
Adjusted rate ratio
(95% confidence
interval)2
Primary outcome
IBD 316 11,005 1.14 (1.02–1.28) 1.11 (0.99–1.24)
Subgroup analyses
12–19 Years 152 3,318 1.26 (1.07–1.48) 1.15 (0.98–1.36)
20–29 Years 164 7,687 1.35 (1.16–1.58) 1.07 (0.91–1.25)
UC 139 4,612 1.20 (1.02–1.42) 1.19 (1.00–1.42)
Crohn’s disease 205 7,263 1.13 (0.98–1.29) 1.07 (0.93–1.23)
Abbreviations: IBD, inflammatory bowel disease; UC, ulcerative colitis.
1The number of observations (n) in each group includes multiple observations for some patients, because patients were allowed to enter different cohorts at
different times, or reenter the same cohort, following a period of no prescription of relevant medications forX365 days. There were 184,824 unique patients in
the topical acne medication group and 1,526,946 in the unexposed group.
2Poisson regression model estimates adjusted for age; sex; socioeconomic status; receipt in the year preceding cohort entry of tetracyclines, erythromycin, oral con-
traceptives, or nonsteroidal antiinflammatory drugs; any physician visit or hospital admission; and any gastrointestinal diagnosis in the year preceding cohort entry.
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involvement is well documented in acne fulminans, and case
reports describe acne fulminans in the setting of IBD (McAuley
and Miller, 1985; Wakabayashi et al., 2011; Zaba et al.,
2011). Acne has also been described as an element of other
systemic inflammatory syndromes (Kahn and Chamot, 1992;
Lindor et al., 1997). Moreover, an association between
hidradenitis suppurativa and IBD has recently been
suggested; and misdiagnosis of the two conditions is a
possibility (van der Zee et al., 2010).
In patients with a previous history of IBD, we speculate that
the paradoxically lower risk of exacerbations with isotretinoin
reflects the selective avoidance of isotretinoin and the pre-
ferential use of topical medications in these patients. Con-
versely, it may represent a genuine protective effect, perhaps
on the basis of retinoid-mediated attenuation of intestinal
inflammation through the activation of peroxisome prolifera-
tor-activated receptor-g, the primary site of action of amino-
salicylate drugs used for IBD (Dubuquoy et al., 2002, 2006;
Zouboulis, 2006).
Some limitations of our study merit emphasis. We had
incomplete information regarding patient-level characteristics
including family history of IBD, ethnicity, and smoking status.
However, this limitation applies equally to all study groups. We
used a single code for IBD as the outcome measure. Although
sensitive, the specificity and positive predictive value of a
single code may be low. However, our findings were replicated
in a secondary analysis using a stricter definition of IBD.
In summary, we found that neither isotretinoin nor topical
acne medications were associated with a statistically signifi-
cant increase in the risk of IBD. However, supplementary
analyses suggested associations in certain subsets of patients.
In general, our findings argue against an association between
isotretinoin and IBD but do suggest a possible association
between IBD and acne itself, rather than its treatment. Further
research is necessary to explore this possibility.
MATERIALS AND METHODS
Setting and source population
We conducted a population-based retrospective cohort study among
residents of British Columbia, Canada, aged 12–29 years, between
1 January 1997 and 31 December 2008. British Columbia is Canada’s
third most populous province, with a population of approximately 4.5
million. This study was approved by the Clinical Research Ethics
Board of the University of British Columbia, and data access was
provided by the British Columbia Ministry of Health. Because we
used deidentified data from existing administrative databases, indivi-
dual patient consent was not required.
Data sources
We obtained prescription drug data from the British Columbia
PharmaNet database, which contains a record of all outpatient
prescriptions dispensed to British Columbia residents. Using
encrypted unique personal health numbers, we linked these records
with other comprehensive provincial physician billing claim records
and hospital visits. We used the British Columbia Medical Services
Plan database to extract physician billing records and the Canadian
Institute for Health Information Discharge Abstract Database to
identify diagnostic information regarding all acute care hospital
admissions in the province. The British Columbia Medical Services
Plan covers all residents of the province with the exclusion of
approximately 4% of residents who are federally insured (e.g.,
aboriginal people, prisoners, and military).
The PharmaNet system includes all prescriptions dispensed at
community pharmacies. The system performs data quality checks,
and prescriptions are linked by unique personal health numbers to
province-wide databases for hospitalizations and physician visits.
Data on hospitalizations were obtained from the Canadian Institute
for Health Information, which collects hospital data for all Canadian
provinces, including Ontario where the data have been evaluated for
accuracy (Williams and Young, 1996).
Study design
We conducted a retrospective cohort study involving two groups of
patients treated with acne medications. The first group included
participants who commenced treatment with oral isotretinoin; in this
group, we anticipated an association between drug therapy and
incident IBD. The second group consisted of patients who com-
menced a topical acne preparation (benzoyl peroxide, erythromycin,
clindamycin, retinoic acid, or adapalene). We included this group of
patients to contextualize any positive association between isotretinoin
and IBD, anticipating no association between topical acne prepara-
tions and IBD. Treatment initiation was defined as a new prescription
Table 4. Acne therapies and risk of hospital admission for inflammatory bowel disease in patients with a history
of disease
Events among
isotretinoin group
(n¼349)1
Events among topical
acne group
(n¼1,791)1
Events among
unexposed group
(n¼ 60,454)1
Unadjusted rate ratio
(95% confidence
interval)
Adjusted rate ratio
(95% confidence
interval)2
Isotretinoin versus
unexposed
14 — 3,582 0.64 (0.38–1.09) 0.75 (0.43–1.27)
Topical acne
medications versus
unexposed
— 144 3,582 1.37 (1.16–1.62) 1.38 (1.16–1.63)
1The number of observations (n) in each group includes multiple observations for some patients, because patients were allowed to enter different cohorts at
different times, or reenter the same cohort, following a period of no prescriptions for relevant medications for X365 days. There were 326 unique patients in
the isotretinoin group, 1,518 in the topical acne medication group, and 18,088 in the unexposed group.
2Poisson regression model estimates adjusted for age; sex; socioeconomic status; receipt in the year preceding cohort entry of tetracyclines, erythromycin, oral con-
traceptives, or nonsteroidal antiinflammatory drugs; any physician visit or hospital admission; and any gastrointestinal diagnosis in the year preceding cohort entry.
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for a study drug with no prescriptions for the same drug in the
preceding 365 days, and we defined the index date as the date on
which the prescription was dispensed. As previous reports suggest
that some cases of IBD could develop within days from starting
isotretinoin, a minimum exposure period for inclusion in the study
was not imposed (Shale et al., 2009).
We restricted the analysis to patients aged 12–29 years because
they represent the majority of isotretinoin recipients (Chen et al.,
2002). To eliminate the possibility of residual isotretinoin effect,
patients were excluded from the topical acne medication group if
they had received a prescription for isotretinoin in the 365 days
before index date. Because a large number of patients prescribed
isotretinoin also have antecedent use of topical medications, the
corresponding restriction was not applied. We required that all study
participants be residents of British Columbia for at least 5 years before
entering the study, as determined by enrollment in the provincial
Medical Services Plan.
For all analyses, the entire population of untreated British Columbia
residents aged 12–29 years served as the reference group. Patients
were evaluated for enrollment in the reference group on a randomly
assigned calendar date for each individual. On the anniversary of this
date each year, each patient was enrolled in the reference group with
their anniversary date as a new index date, provided they still met the
inclusion criteria at that time. Patients were excluded from the
reference group if they had received a prescription for isotretinoin
or a topical acne medication in the 365 days before each index date.
We observed each study participant for up to 1 year following the
index date to identify outcomes of interest. We selected this approach
because a review of the existing literature suggested that all cases of
IBD associated with isotretinoin developed within 1 year of starting
the drug (Shale et al., 2009). Moreover, a course of treatment with
isotretinoin typically lasts 16 weeks (Shalita et al., 1983; Layton et al.,
1993). Therefore, this design allowed treated and untreated patients to
enter the analysis more than once, either in the same cohort (as might
occur with successive prescriptions for topical acne medications at
intervals 41 year) or in another cohort (as might occur when
untreated patients later progress to treatment, for example) with
different index dates each time. Each entry was considered a
discrete observation. Patients in the topical acne medication group
were censored if they switched to isotretinoin (a common clinical
occurrence), and patients in the reference group were censored if they
commenced any acne therapy. We also censored at time of death, the
end of medical services coverage, or the end of study period (31
December 2008), whichever occurred first.
Statistical analysis
The primary analysis examined the time to any clinical encounter
(physician visit or hospital admission) for IBD among patients with no
diagnosis of either UC or Crohn’s disease (International Classification
of Disease-9: 555 and 556, and International Classification of
Disease-10: K50 and K51) in the 5 years before the index date. Using
the Poisson regression, we adjusted for potential confounders includ-
ing age, gender, and socioeconomic status (patients receiving a public
subsidy for BC Medical Services Plan premiums were considered to
have low-income status). We also adjusted for various aspects of
medical care before cohort entry including prescriptions in the year
before the index date (tetracyclines, erythromycin, oral contracep-
tives, or nonsteroidal antiinflammatory drugs), and any physician visit
or hospital admission in 1 year before the index date for any
gastrointestinal diagnosis, because these may have presaged the
development of IBD. Finally, to address any potential discrepancy
in access to health care, we adjusted for any physician visits in 1 year
before the index date.
We conducted several prespecified secondary analyses to test the
robustness of our conclusions. We first stratified by age (12–19 years
and 20–29 years), reasoning that younger patients would be more
likely to receive isotretinoin for acne, whereas older patients some-
times receive the drug for rosacea. We also conducted separate
analyses of Crohn’s disease and UC, because the diseases have
different pathogeneses. Patients coded as having both diagnoses were
included in both of these analyses. Finally, given the possibility that
isotretinoin may exacerbate preexisting IBD, we conducted a sec-
ondary analysis of the risk of hospital admission (as opposed to any
medical encounter) for IBD among patients with a history of IBD in
the 5 years before the index date.
Finally, because a single encounter for IBD may not be specific, we
conducted a sensitivity analysis using a stricter definition of IBD. In
this analysis, we required two clinical encounters (physician claims or
hospital admissions) for IBD, or one such encounter along with
subsequent prescription of a drug used to treat IBD (including
systemic corticosteroids, sulfasalazine and related drugs, methotrex-
ate, azathioprine, or 6-mercaptopurine). For all analyses we used a
two-tailed type 1 error rate of 0.05 as the threshold for statistical
significance. All analyses were performed using SAS version 9.1.2
(SAS Institute, Cary NC).
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